



US009408945B2

(12) **United States Patent**  
**Goessl et al.**

(10) **Patent No.:** **US 9,408,945 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS**  
(75) Inventors: **Andreas Goessl**, Vienna (AT); **Atsushi Edward Osawa**, San Francisco, CA (US); **Cary J. Reich**, Los Gatos, CA (US)  
(73) Assignees: **Baxter International Inc.**, Deerfield, IL (US); **Baxter Healthcare S.A.**, Glattpark (Opfikon) (CH)  
(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 397 days.

4,642,111 A \* 2/1987 Sakamoto et al. .... 424/492  
4,655,211 A 4/1987 Sakamoto et al.  
4,746,514 A 5/1988 Warne  
4,749,689 A 6/1988 Miyata et al.  
4,752,466 A 6/1988 Saferstein et al.  
4,803,075 A 2/1989 Wallace et al.  
4,818,517 A 4/1989 Kwee et al.  
4,832,686 A 5/1989 Anderson  
4,837,285 A 6/1989 Berg et al.  
4,885,161 A 12/1989 Cornell  
4,891,359 A 1/1990 Saferstein et al.  
4,925,677 A 5/1990 Feijen  
4,946,870 A 8/1990 Partain, III et al.  
5,007,916 A 4/1991 Linsky et al.  
5,017,229 A 5/1991 Burns et al.

(Continued)

(21) Appl. No.: **13/150,809**

(22) Filed: **Jun. 1, 2011**

(65) **Prior Publication Data**  
US 2012/0128653 A1 May 24, 2012

**Related U.S. Application Data**

(60) Provisional application No. 61/350,214, filed on Jun. 1, 2010.

(51) **Int. Cl.**  
**A61P 7/04** (2006.01)  
**A61L 24/10** (2006.01)  
**A61K 38/48** (2006.01)  
(52) **U.S. Cl.**  
CPC ..... **A61L 24/104** (2013.01); **A61K 38/4833** (2013.01); **A61L 24/10** (2013.01); **A61L 24/106** (2013.01); **A61L 2400/04** (2013.01)

(58) **Field of Classification Search**  
CPC ..... C12N 9/6429; A61K 38/4833  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2,507,244 A 5/1950 Correll  
2,558,395 A 6/1951 Studer  
4,013,078 A 3/1977 Field  
4,124,705 A 11/1978 Rothman et al.  
4,164,559 A 8/1979 Miyata et al.  
4,179,400 A 12/1979 Tsao et al.  
4,265,233 A 5/1981 Sugitachi et al.  
4,291,013 A 9/1981 Wahlig et al.  
4,292,972 A 10/1981 Pawelchak et al.  
4,298,598 A 11/1981 Schwarz et al.  
4,300,494 A 11/1981 Graiff et al.  
4,347,234 A 8/1982 Wahlig et al.  
4,362,567 A 12/1982 Schwarz et al.  
4,377,572 A 3/1983 Schwarz et al.  
4,424,208 A 1/1984 Wallace et al.  
4,453,939 A 6/1984 Zimmerman et al.  
4,482,386 A 11/1984 Wittwer et al.  
4,515,637 A 5/1985 Cioca  
4,536,387 A 8/1985 Sakamoto et al.  
4,540,410 A 9/1985 Wood et al.  
4,543,332 A 9/1985 Jao et al.  
4,554,156 A 11/1985 Fischer  
4,600,574 A 7/1986 Lindner et al.  
4,640,834 A 2/1987 Eibl et al.

**FOREIGN PATENT DOCUMENTS**

CN 1270240 A 10/2000  
EP 0132983 A 2/1985

(Continued)

**OTHER PUBLICATIONS**

Tang, Xiaolin Charlie, and Michael J. Pikal. "Design of freeze-drying processes for pharmaceuticals: practical advice." *Pharmaceutical research* 21.2 (2004): 191-200.\*

Definition of "lyophilization", *The American Heritage® Medical Dictionary* Copyright © 2007, 2004 by Houghton Mifflin Company, accessed at following URL on Jan. 9, 2016: <http://medical-dictionary.thefreedictionary.com/lyophilization>.\*

International Search Report for PCT/EP2011/059062 mailed Nov. 24, 2011, 22 pages.

International Search Report for PCT/EP2011/059065 mailed Nov. 24, 2011, 22 pages.

(Continued)

*Primary Examiner* — Robert Yamasaki

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

Described is a process for making a dry and stable hemostatic composition, said process comprising

- a) providing a first component comprising a dry preparation of a coagulation inducing agent,
- b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis,
- c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container,
- d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, and
- e) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

**42 Claims, No Drawings**